Monteiro, Lis Marie 
; Löbenberg, Raimar ; Barbosa, Eduardo José ; Araujo, Gabriel Lima Barros de ; Sato, Paula Keiko ; Kanashiro, Edite Hatsumi Yamashiro ; Eliodoro, Raissa Heloisa de Araujo; Rocha, Mussya; Freitas, Vera Lucia Teixeira de ; Fotaki, Nikoletta; Bou-Chacra, Nadia Araci
Source: European Journal of Pharmaceutical Sciences. Unidades: FCF, IMT, FM
Subjects: LIPÍDEOS, LEISHMANIOSE VISCERAL, DOENÇAS NEGLIGENCIADAS, NANOTECNOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MONTEIRO, Lis Marie et al. Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum. European Journal of Pharmaceutical Sciences, v. 169, p. 1-11 art. 106097, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.ejps.2021.106097. Acesso em: 05 out. 2024.APA
Monteiro, L. M., Löbenberg, R., Barbosa, E. J., Araujo, G. L. B. de, Sato, P. K., Kanashiro, E. H. Y., et al. (2022). Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum. European Journal of Pharmaceutical Sciences, 169, 1-11 art. 106097. doi:10.1016/j.ejps.2021.106097NLM
Monteiro LM, Löbenberg R, Barbosa EJ, Araujo GLB de, Sato PK, Kanashiro EHY, Eliodoro RH de A, Rocha M, Freitas VLT de, Fotaki N, Bou-Chacra NA. Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum [Internet]. European Journal of Pharmaceutical Sciences. 2022 ; 169 1-11 art. 106097.[citado 2024 out. 05 ] Available from: https://doi.org/10.1016/j.ejps.2021.106097Vancouver
Monteiro LM, Löbenberg R, Barbosa EJ, Araujo GLB de, Sato PK, Kanashiro EHY, Eliodoro RH de A, Rocha M, Freitas VLT de, Fotaki N, Bou-Chacra NA. Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum [Internet]. European Journal of Pharmaceutical Sciences. 2022 ; 169 1-11 art. 106097.[citado 2024 out. 05 ] Available from: https://doi.org/10.1016/j.ejps.2021.106097
